Myeloma

Top Story

Subcutaneous daratumumab attains deep response in multiple myeloma

Subcutaneous daratumumab attains deep response in multiple myeloma
July 22, 2019
Meeting News

ASH announces award recipients

July 15, 2019
Several distinguished leaders in hematology will be honored with awards and special lectures at this year’s ASH Annual Meeting and Exposition, scheduled for Dec…
FDA News

FDA approves Xpovio regimen for patients with relapsed or refractory multiple myeloma

July 3, 2019
The FDA today approved selinexor in combination with corticosteroid dexamethasone for the treatment of relapsed or refractory multiple myeloma, according to press…
Feature

Dana-Farber clinic to focus on blood cancer precursor conditions

June 28, 2019
Dana-Farber Cancer Institute opened a new clinic designed to improve clinical care and monitoring for individuals with precursor conditions that can progress to blood…
More Headlines »
CME

2019 Texas Oncology Clinical Educational Symposium

This activity is supported by educational grants from AbbVie, Inc.; Celgene Corporation; Novartis Pharmaceuticals Corporation; Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc.; Takeda Oncology; and Verastem, Inc..

Clinical outcomes for advanced cancers continue to improve through the identification as well as the development of…
More »
Video

Baseball Hall of Famer: Physician’s confidence affects patients

September 26, 2017
More »
Resource Centers
At Issue: Multiple Myeloma Resource Center

At Issue: Multiple Myeloma Resource Center